Biomerica (BMRA) Long-Term Deferred Tax (2011 - 2023)

Biomerica (BMRA) reported Long-Term Deferred Tax of $8.1 million for Q1 2023, up 4.39% sequentially from $7.7 million in Q4 2022.

Biomerica (BMRA) Long-Term Deferred Tax (2011 - 2023) Analysis & Trends

Biomerica (BMRA) has 11 years of Long-Term Deferred Tax data on file, last reported at $8.1 million in Q1 2023.

  • For the quarter ending Q1 2023, Long-Term Deferred Tax changed N/A year-over-year to $8.1 million; the trailing twelve-month figure through Feb 2023 stood at $8.1 million (changed N/A YoY), and the FY2022 full-year result was $7.0 million, changed N/A from the prior year.
  • Long-Term Deferred Tax advanced to $8.1 million in Q1 2023, from $7.7 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $8.1 million in Q1 2023 to a low of $10000.0 in Q1 2019.
  • A 3-year average of $6.0 million and a median of $7.4 million in 2022 frame the typical range for Long-Term Deferred Tax.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn
9 Smith & Nephew 25.80 Bn 25.22 Bn -
10 Biomerica 4.85 Mn 3.51 Mn -44,000.00

Historic Data

Download Data
DateValue
Feb 28, 2023 8.09 Mn
Nov 30, 2022 7.75 Mn
Aug 31, 2022 7.40 Mn
May 31, 2022 6.97 Mn
Feb 28, 2019 10,000.00
Nov 30, 2018 10,000.00
Aug 31, 2018 10,000.00
May 31, 2018 10,000.00
Aug 31, 2017 41,000.00
May 31, 2017 41,000.00
Feb 28, 2017 41,000.00
Nov 30, 2016 41,000.00
Aug 31, 2016 41,000.00
May 31, 2016 94,000.00
Feb 29, 2016 998,000.00
Nov 30, 2015 873,000.00
Aug 31, 2015 670,000.00
May 31, 2015 744,000.00
Feb 28, 2015 359,000.00
Nov 30, 2014 359,000.00